Atossa Therapeutics Inc. Common Stock (ATOS)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look first for a durable business earning cash. Atossa does not fit that mold. It is a clinical-stage biopharmaceutical company with no reported revenue, 16 employees, and a lead candidate in Phase 2. In fiscal 2025, the year ended 2025-12-31, it reported a net loss of $34.8 million; in fiscal 2024, a loss of $25.5 million; and in fiscal 2023, a loss of $30.1 million. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $8.5 million. That is the opposite of the compounding machine I want. Financial health is poor. Trailing free cash flow is negative $35.8 million, which against a $25.5 million market cap at the 2026-10-13 close is a negative 140.1% FCF yield by FairStock's calculation. FairStock also shows ROE of -89.23% and ROCE of -50.69%. The Piotroski score is 1/9 and the Altman Z-score is -7.72, both signaling distress. The FairStock P/B of 0.95 might suggest the shares trade near book value, but with cash burning faster than the market value, book value is not stable. Valuation is difficult because FairStock's P/E is -0.58, and there is no revenue to discount. The FairStock score is 28/100, and the Lynch category is none because of four straight loss years. Growth is not revenue growth but trial progress, and that is binary. A Phase 2 oncology asset could be valuable if the data are strong, but I cannot underwrite that from these figures. For a Graham-style margin of safety, I see none. This is a speculative drug-development option, not a proven business.

In plain English: Atossa Therapeutics is a tiny company testing a breast cancer drug with only 16 employees. It has no reported revenue and has lost money for years, while burning through cash. Its price is close to the accounting value of its net assets, but because the business is not yet profitable and is using cash quickly, it looks speculative rather than a stable bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer